Actively Recruiting
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2025-11-25
1500
Participants Needed
9
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bronchiectasis is a heterogeneous airway disease with diverse causes, making precise diagnosis, prognosis, and treatment response prediction challenging. Identifying patient subgroups (phenotypes) and molecular profiles (endotypes) can enhance individualized assessment and management. While prior studies, primarily in European populations, have identified key phenotypes and endotypes, their relevance to Chinese patients remains unclear due to geographic and clinical differences. Specific causes of bronchiectasis, such as allergic bronchopulmonary aspergillosis (ABPA) and primary ciliary dyskinesia (PCD), may also exhibit distinct pathophysiology requiring further exploration. The C-BRIDGE Study seeks to characterize phenotypes and endotypes in Chinese bronchiectasis patients during stable disease and exacerbations, evaluate differences in clinical outcomes across these subgroups, and develop personalized medicine strategies based on these findings, applicable in China and globally. Primary Objective: To identify molecular endotypes of bronchiectasis that accurately predict prognosis and guide treatment responses. Secondary Objectives: To characterize molecular endotypes of stable bronchiectasis in Chinese patients. To define molecular endotypes of bronchiectasis exacerbations in Chinese patients. To investigate molecular endotypes specific to allergic bronchopulmonary aspergillosis (ABPA). To explore genotypes and inflammatory endotypes of cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) in Chinese patients. To validate candidate biomarkers for stable and exacerbation endotypes to support stratified medicine. To conduct in vivo or in vitro proof-of-concept studies using phenotypic data to identify patient subgroups likely to benefit from specific pharmacological interventions. Study Design: This observational cohort study will link identified patient subgroups with meaningful clinical outcomes to inform prognosis and optimize treatment strategies.
CONDITIONS
Official Title
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A prior CT scan confirming bronchiectasis, accompanied by a compatible clinical syndrome including cough, sputum production, and/or recurrent respiratory tract infections.
- Clinically stable for 4 weeks at screening, with no antibiotic or corticosteroid treatment for a pulmonary exacerbation in the preceding 4 weeks.
- Aged between 18 and 85 years.
- Ability to provide informed consent.
You will not qualify if you...
- Unable to provide informed consent.
- Age under 18 years.
- Active tuberculosis infection.
- Use of antibiotics or corticosteroids for a pulmonary exacerbation within the past 4 weeks.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Lin Liu
Guiyang, Guizhou, China
Actively Recruiting
2
Lei Song
Changchun, Jilin, China
Actively Recruiting
3
Qian Qi
Jinan, Shangdong, China
Actively Recruiting
4
He-feng Chen
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
5
Zhou-fang Mei
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
6
Jun She
Shanghai, Shanghai Municipality, China, 200437
Actively Recruiting
7
Xue-ling Wu
Shanghai, Shanghai Municipality, China, 200437
Actively Recruiting
8
Yong-hua Gao
Shanghai, Shanghai Municipality, China, 200437
Actively Recruiting
9
Xiao-long Ma
Jiaxing, Zhejiang, China
Actively Recruiting
Research Team
Y
Yong-hua Gao, Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here